LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 96 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,800 | -16.3% | 10,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $14,100 | -6.0% | 10,000 | 0.0% | 0.00% | -20.0% |
| Q1 2023 | $15,000 | +28.2% | 10,000 | 0.0% | 0.01% | +25.0% |
| Q4 2022 | $11,700 | -26.9% | 10,000 | 0.0% | 0.00% | -42.9% |
| Q2 2022 | $16,000 | +6.7% | 10,000 | 0.0% | 0.01% | +16.7% |
| Q1 2022 | $15,000 | -40.0% | 10,000 | 0.0% | 0.01% | -33.3% |
| Q4 2021 | $25,000 | 0.0% | 10,000 | 0.0% | 0.01% | -10.0% |
| Q3 2021 | $25,000 | -13.8% | 10,000 | 0.0% | 0.01% | -16.7% |
| Q2 2021 | $29,000 | +20.8% | 10,000 | 0.0% | 0.01% | +20.0% |
| Q1 2021 | $24,000 | +33.3% | 10,000 | 0.0% | 0.01% | +25.0% |
| Q4 2020 | $18,000 | +100.0% | 10,000 | 0.0% | 0.01% | +60.0% |
| Q3 2020 | $9,000 | 0.0% | 10,000 | 0.0% | 0.01% | 0.0% |
| Q2 2020 | $9,000 | +12.5% | 10,000 | 0.0% | 0.01% | -28.6% |
| Q1 2020 | $8,000 | -11.1% | 10,000 | 0.0% | 0.01% | -12.5% |
| Q4 2019 | $9,000 | – | 10,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 34,005,379 | $28,160,000 | 3.29% |
| Defender Capital, LLC. | 4,416,590 | $3,657,000 | 2.67% |
| Prescott General Partners LLC | 1,851,851 | $1,534,000 | 0.13% |
| Laidlaw Wealth Management LLC | 107,379 | $89,000 | 0.06% |
| Northeast Financial Consultants Inc | 523,756 | $434,000 | 0.05% |
| Beirne Wealth Consulting Services, LLC | 45,000 | $37,000 | 0.04% |
| DAFNA Capital Management LLC | 95,000 | $79,000 | 0.03% |
| Summit X, LLC | 30,700 | $25,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 529,039 | $438,000 | 0.01% |
| Keudell/Morrison Wealth Management | 10,105 | $8,000 | 0.01% |